Voyager Therapeutics Announces Preclinical Alzheimer's Gene Therapy Data
Voyager Therapeutics (NASDAQ: VYGR) announced preclinical data for its Alzheimer’s gene therapy, VY1706, showing a reduction of tau protein in non-human primates by up to 64%. The company plans to request FDA authorization for human trials and expects first-in-human dosing later in 2026. Voyager also has an anti-tau antibody program underway.
Tickers: $VYGR
Topics: Alzheimer's disease FDA authorization preclinical data Voyager Therapeutics